Evaluating recovery from neuromuscular blocking agents
Estimation of Neuromuscular Transmission Recovery After Rocuronium Induced Block - Validation Study of a New Algorithm
Erasme University Hospital · NCT05716282
This study is testing a new way to estimate how long it takes for patients to recover from muscle relaxation after surgery using a specific medication called rocuronium.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Erasme University Hospital (other) |
| Locations | 1 site (Brussels) |
| Trial ID | NCT05716282 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate a mathematical model that estimates the time required for patients to recover from neuromuscular blockade after receiving a single dose of rocuronium during surgery. By measuring neuromuscular transmission at the adductor pollicis using the TOFScan device, the study will assess the accuracy and precision of the recovery time estimation based on initial train-of-four measurements. The goal is to improve monitoring and management of neuromuscular recovery in surgical patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older scheduled for surgery requiring a single bolus of 0.6 mg/kg of rocuronium.
Not a fit: Patients with known allergies to rocuronium, significant renal or hepatic insufficiencies, or those with a BMI outside the range of 20-30 kg/m2 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate predictions of recovery times, enhancing patient safety and optimizing surgical outcomes.
How similar studies have performed: Previous studies have explored similar methodologies for neuromuscular monitoring, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Patients scheduled for surgery with a single bolus administration of 0.6 mg/kg of rocuronium Exclusion Criteria: * patient refusal to participate * known or suspected allergy to rocuronium * Body mass index \< 20 kg/m2 * Body mass index \> 30 kg/m2 * hepatic insufficiency, either clinical or hepatic test abnormalities * renal insufficiency defined as a clearance \< 40 mL/min (calculated by the Modification of diet in renal disease (MDRD) formula
Where this trial is running
Brussels
- CUB Hôpital Erasme — Brussels, Belgium (RECRUITING)
Study contacts
- Study coordinator: Denis Schmartz, MD
- Email: denis.schmartz@hubruxelles.be
- Phone: +3225553919
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neuromuscular Blockade Monitoring, Neuromuscular Blocking Agents, Neuromuscular Monitoring, Neuromuscular Nondepolarizing Agents